Lamivudine, Entecavir, or Tenofovir Treatment of Hepatitis B Infection: Effects on Calcium, Phosphate, FGF23 and Indicators of Bone Metabolism
Background. Patients with chronic hepatitis B virus (HBV) are often treated with nucleoside/nucleotide antiviral agents and metabolic bone toxicity is a possible concern.Objective. To determine the relationships between fibroblast growth factor 23 (FGF23), a phosphaturic hormone, bone mineral densit...
Main Authors: | Ramesh Saeedi, Ali Mojebi-Mogharar, Supna K. Sandhu, Joshua A. Dubland, Jo-Ann Ford, Masoud Yousefi, Morris Pudek, Daniel T. Holmes, Siegfried R. Erb, Wing C. Peter Kwan, David L Kendler, Eric M. Yoshida |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-03-01
|
Series: | Annals of Hepatology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268119303837 |
Similar Items
-
Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis
by: Aoran Luo, et al.
Published: (2018-09-01) -
[Tenofovir and entecavir for chronic hepatitis B infection treatment: a single-center experience]
by: Fabio Tarsetti, et al.
Published: (2015-12-01) -
Dyspnea and Generalized Paresthesias Due to a Rare Metabolic Disorder: Severe Hypophosphatemia
by: Seyit Ahmet Uslu, et al.
Published: (2016-06-01) -
Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British paediatric and adolescent bone group recommendations
by: Raja Padidela, et al.
Published: (2020-10-01) -
Hemato-biochemical and clinico-epidemiological aspects of parturient hemoglobinuria in Nili-Ravi buffaloes
by: A. Khan, et al.
Published: (2010-02-01)